Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Reaffirmed by Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note published on Thursday, Benzinga reports. They currently have a $235.00 price objective on the biotechnology company’s stock.

Several other research firms have also commented on SRPT. Barclays increased their price objective on shares of Sarepta Therapeutics from $185.00 to $226.00 and gave the company an overweight rating in a research report on Friday, June 21st. Wedbush reaffirmed an outperform rating and issued a $224.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, February 29th. SVB Leerink raised their price target on shares of Sarepta Therapeutics from $165.00 to $230.00 and gave the stock an outperform rating in a research note on Monday, June 24th. Cantor Fitzgerald reaffirmed a neutral rating and issued a $128.00 price target on shares of Sarepta Therapeutics in a research note on Friday, June 21st. Finally, JPMorgan Chase & Co. reduced their price target on shares of Sarepta Therapeutics from $177.00 to $175.00 and set an overweight rating on the stock in a research note on Friday, May 3rd. Five research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of Moderate Buy and a consensus target price of $185.06.

Sarepta Therapeutics Stock Up 0.0 %

SRPT opened at $158.00 on Thursday. The company has a quick ratio of 3.44, a current ratio of 4.05 and a debt-to-equity ratio of 1.18. The firm has a 50 day moving average price of $129.74 and a 200-day moving average price of $122.66. Sarepta Therapeutics has a twelve month low of $55.25 and a twelve month high of $173.25. The stock has a market capitalization of $14.93 billion, a price-to-earnings ratio of 1,436.36 and a beta of 0.96.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.84. The business had revenue of $413.50 million during the quarter, compared to analyst estimates of $375.52 million. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The company’s revenue was up 63.1% on a year-over-year basis. During the same period in the prior year, the business posted ($1.44) earnings per share. Equities research analysts forecast that Sarepta Therapeutics will post 3.71 earnings per share for the current year.

Insider Activity at Sarepta Therapeutics

In related news, insider Dallan Murray sold 3,635 shares of the business’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total value of $508,900.00. Following the sale, the insider now directly owns 18,125 shares in the company, valued at approximately $2,537,500. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, insider Bilal Arif sold 7,859 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $163.08, for a total value of $1,281,645.72. Following the completion of the transaction, the insider now directly owns 21,261 shares of the company’s stock, valued at $3,467,243.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Dallan Murray sold 3,635 shares of the stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total value of $508,900.00. Following the completion of the sale, the insider now directly owns 18,125 shares of the company’s stock, valued at $2,537,500. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 50,451 shares of company stock worth $8,086,386. Company insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Several large investors have recently modified their holdings of the company. Vanguard Group Inc. grew its position in Sarepta Therapeutics by 2.8% in the 4th quarter. Vanguard Group Inc. now owns 8,816,124 shares of the biotechnology company’s stock valued at $850,139,000 after buying an additional 243,180 shares during the last quarter. Capital International Investors lifted its holdings in Sarepta Therapeutics by 1.6% in the first quarter. Capital International Investors now owns 4,817,517 shares of the biotechnology company’s stock valued at $623,676,000 after acquiring an additional 76,032 shares during the period. Avoro Capital Advisors LLC lifted its holdings in Sarepta Therapeutics by 7.9% in the fourth quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock valued at $418,935,000 after acquiring an additional 319,444 shares during the period. Wellington Management Group LLP lifted its holdings in Sarepta Therapeutics by 5.6% in the fourth quarter. Wellington Management Group LLP now owns 4,127,610 shares of the biotechnology company’s stock valued at $398,025,000 after acquiring an additional 217,810 shares during the period. Finally, Farallon Capital Management LLC lifted its holdings in Sarepta Therapeutics by 102.8% in the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after acquiring an additional 1,243,427 shares during the period. 86.68% of the stock is owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.